Patent · US Active

Human alpha-folate receptor chimeric antigen receptor

US12122829B2 · kind B2 · utility

0Cited by

56References

3Claims

0Family size

Assignees

The Trustees of the University of Pennsylvania · US
Fondazione IRCCS Istituto Nazionale Dei Tumori · IT

Inventors

Daniel J. Powell, Jr. · Bala-Cynwyd, US
Mariangela Figini · Milano, IT
Silvana Canevari · Segrate, IT

Key dates

Filing date	Oct 21, 2020
Grant date	Oct 22, 2024
Priority date	—
Expiry date	Aug 16, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/03
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FRα binding domain is fully human, thereby preventing a host immune response.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.